```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14   FSTA enhanced with Japanese patents
 NEWS 15  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09   INSPEC enhanced with 1898-1968 archive

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:55:34 ON 24 AUG 2006

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:55:47 ON 24 AUG 2006
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2006 HIGHEST RN 903481-59-4
DICTIONARY FILE UPDATES: 22 AUG 2006 HIGHEST RN 903481-59-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s loteprednol
L1 3 LOTEPREDNOL

=> d L1 1-3 str cn rn

L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11β,17α)-, mixt. with O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→4)]-2-deoxy-D-streptamine (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Loteprednol etabonate-tobramycin mixt.
RN 863983-05-5 REGISTRY

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry.



L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Androsta-1,4-diene-17-carboxylic acid, 11,17-dihydroxy-3-oxo-, chloromethyl ester, (11β,17α)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Loteprednol
RN 129260-79-3 REGISTRY

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11β,17α)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Alrex
CN CDDD 5604
CN HGP 1
CN Lenoxin
CN Lotemax
CN Loteprednol etabonate
CN P 5604
RN 82034-46-6 REGISTRY

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.34	11.55

FILE 'CAPLUS' ENTERED AT 09:57:00 ON 24 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s L1
L2 132 L1

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3 132 DUP REM L2 (0 DUPLICATES REMOVED)

=> e asthma
E1 1 ASTHIONALIDE/BI
E2 1 ASTHM/BI
E3 31996 --> ASTHMA/BI
E4 1 ASTHMA1/BI
E5 1 ASTHMA2/BI
E6 1 ASTHMAAND/BI
E7 5 ASTHMAGEN/BI
E8 5 ASTHMAGENIC/BI
E9 11 ASTHMAGENS/BI
E10 11 ASTHMALIKE/BI
E11 1 ASTHMAM/BI
E12 1 ASTHMAN/BI

=> s e3 or e7 or e8 or e10

```
         31996 ASTHMA/BI
            21 ASTHMAS/BI
         32004 ASTHMA/BI
                 ((ASTHMA OR ASTHMAS)/BI)
             5 ASTHMAGEN/BI
            11 ASTHMAGENS/BI
            13 ASTHMAGEN/BI
                 ((ASTHMAGEN OR ASTHMAGENS)/BI)
             5 ASTHMAGENIC/BI
            11 ASTHMALIKE/BI
L4       32011 ASTHMA/BI OR ASTHMAGEN/BI OR ASTHMAGENIC/BI OR ASTHMALIKE/BI

=> s L2 and L4
L5           7 L2 AND L4

=> d 1-7 L5 ibib abs

L5   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:735068  CAPLUS
DOCUMENT NUMBER:         143:199889
TITLE:                   Combination of anticholinergics and glucocorticoids
                         for the long-term treatment of asthma and
                         COPD
INVENTOR(S):             Goede, Joachim; Maus, Joachim; Cnota, Peter Jurgen;
                         Szelenyi, Istvan
PATENT ASSIGNEE(S):      Sofotec GmbH & Co. KG, Germany
SOURCE:                  U.S. Pat. Appl. Publ., 5 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2005175548         A1    20050811    US 2005-51468           20050207
     WO 2005074918         A1    20050818    WO 2005-EP652           20050124
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                       US 2004-541956P     P  20040206
AB   The present invention describes a combination of topically inhaled
     medicinal formulations comprising an anticholinergic component and a
     glucocorticosteroid component and its use in the symptomatic and
     prophylactic treatment of diseases of the respiratory tract, especially with an
     obstructive component or underlying inflammation like asthma and
     chronic obstructive pulmonary disease (COPD). It further comprises the
     presentation of this combination in a locally applied (inhaled)
     formulation and application in an inhalation device for instance in the
     Novolizer.

L5   ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:409325  CAPLUS
DOCUMENT NUMBER:         142:435859
TITLE:                   Soft steroid compositions for use in dry powder
                         inhalants
```

INVENTOR(S): Goller, Michael I.; Li, Qi; Ly, Jade; Momin, Mohammed Nurul; Salas, Katherine; Ukeje, Anayo Michael; Yanamandra, Ramesh; Zeng, Xian-Ming
PATENT ASSIGNEE(S): Ivax Corporation, USA; Norton Healthcare, Ltd.
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041980	A1	20050512	WO 2004-US36477	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285592	A1	20050512	AU 2004-285592	20041103
CA 2544422	AA	20050512	CA 2004-2544422	20041103
EP 1684767	A1	20060802	EP 2004-817524	20041103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-517324P P 20031103
WO 2004-US36477 W 20041103
OTHER SOURCE(S): MARPAT 142:435859
AB A method of producing a composition containing a soft steroid is disclosed. The composition is suitable for administration via a dry powder inhalant. A blend consisted of 4.7 etiprednol dicloacetate and 95.3%by weight α-lactose monohydrate was prepared by mixing sieved particles.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:468794 CAPLUS
DOCUMENT NUMBER: 141:100057
TITLE: Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate
AUTHOR(S): Szelenyi, I.; Hermann, R.; Petzold, U.; Pahl, A.; Hochhaus, G.
CORPORATE SOURCE: Institute for Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University of Erlangen, Germany
SOURCE: Pharmazie (2004), 59(5), 409-411
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Allergic conditions contribute significantly to the burden of chronic disease in the industrialized world. The increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. Despite considerable efforts of the pharmaceutical industry, the leukotriene antagonists were the only new class of asthma treatments to be licensed in the past 30 yr. Topical glucocorticoids

(GCs) are the most potent and effective therapy for treating allergic diseases. However, their use is limited by diverse undesired effects. Changes in pharmacokinetic parameters of GCs may be an interesting and promising approach to improve efficacy and safety of inhaled GCs. Loteprednol etabonate has been developed on the basis of the retrometabolic drug design. In animal studies, it has been demonstrated to have long-lasting anti-allergic (anti-asthmatic) effects without influencing the hypothalamic-pituitary axis (HPA). This soft steroid is now in phase III of the clin. development. Recently, loteprednol has been proven to be effective in the management of allergic rhinitis (400 μg once daily). No suppression of HPA was observed at clin. effective and higher doses. In conclusion, loteprednol as the first representative of soft steroids elicits marked anti-inflammatory effects, but has no impact on endocrine responses. It may represent a promising new therapy in the treatment of allergic rhinitis and asthma.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:203704 CAPLUS
DOCUMENT NUMBER: 140:229455
TITLE: Combination of glucocorticoids and PDE-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and COPD
INVENTOR(S): Locher, Mathias; Hermann, Robert
PATENT ASSIGNEE(S): Viatris G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019984	A1	20040311	WO 2003-EP8607	20030804
W: AU, BR, CA, CN, CO, CZ, GE, HR, ID, IL, IN, JP, KR, LT, LV, MD, MK, MX, NO, NZ, PL, SG, UA, US, UZ, YU, ZA				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2492645	AA	20040311	CA 2003-2492645	20030804
AU 2003255365	A1	20040319	AU 2003-255365	20030804
EP 1526870	A1	20050504	EP 2003-790851	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, SK				
JP 2005539042	T2	20051222	JP 2004-531853	20030804
US 2005288265	A1	20051229	US 2005-523802	20050209
NO 2005001212	A	20050308	NO 2005-1212	20050308

PRIORITY APPLN. INFO.: DE 2002-10236688 A 20020809
WO 2003-EP8607 W 20030804

AB The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phosphodiesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or sep. administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD). Formulation of glucocorticoids and PDE-4-inhibitors can be prepared sep. and applied at the same time or at different times during the day; also combinations can be formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:832575 CAPLUS
DOCUMENT NUMBER: 137:346196
TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent
INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed
PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 872 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
WO 2002085308	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256359	A1	20021105	AU 2002-256359	20020423
US 2004049022	A1	20040311	US 2003-627930	20030725
PRIORITY APPLN. INFO.:			US 2001-286137P	P 20010424
			WO 2002-US13135	A 20020423
			WO 2002-US13143	A2 20020423

OTHER SOURCE(S): MARPAT 137:346196

AB This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addition, they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:385539 CAPLUS
DOCUMENT NUMBER: 137:346268
TITLE: Design and development of a soft corticosteroid, loteprednol etabonate
AUTHOR(S): Bodor, Nicholas; Buchwald, Peter
CORPORATE SOURCE: University of Florida, Gainesville, FL, USA
SOURCE: Lung Biology in Health and Disease (2002), 163(Inhaled Steroids in Asthma), 541-564
CODEN: LBHDD7; ISSN: 0362-3181
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Topical application of active corticosteroids that undergo nonoxidative, extrahepatic metabolism can provide improved, safer treatments of allergic diseases by minimizing the risk of systemic absorption and, therefore, the occurrence of side effects. Loteprednol etabonate, a soft corticosteroid that contains 17α-carbonate and 17β ester side chains and that was designed by using an inactive metabolite-based approach, lacks serious side effects and already received FDA approval for use in all inflammatory and allergy-related ophthalmic disorders. Since exptl. evidence indicates that it also produces strong and long-lasting antiinflammatory effect after intranasal or intrapulmonary administration, currently it is being developed for the treatment of allergic conditions, such as rhinitis and asthma.

REFERENCE COUNT: 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:414694 CAPLUS

DOCUMENT NUMBER: 133:261550
TITLE: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways
AUTHOR(S): Szelenyi, Istvan; Hochhaus, Gunther; Heer, Sabine; Kusters, Sabine; Marx, Degenhard; Poppe, Hildegard; Engel, Jurgen
CORPORATE SOURCE: Pulmonary Pharmacology, Corporate Research & Development, ASTA Medica, Frankfurt and Dresden, Germany
SOURCE: Drugs of Today (2000), 36(5), 313-320
CODEN: MDACAP; ISSN: 0025-7656
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 58 refs. There are several approaches for developing new antiallergic/antiasthmatic agents. One of them is the improvement of an existing class of effective drug classes. Due to some undesired effects of intranasal or inhaled corticosteroids, there is a need for better tolerated corticosteroids. Loteprednol etabonate belongs to the so-called class of soft steroids because it is metabolized by a 1-step reaction (hydrolysis) without using the cytochrome P 450 monooxygenase system. In in vitro investigations in human cells, loteprednol inhibited the release of proinflammatory cytokines (e.g., TNF-α, GM-CSF, IL-4, IL-5) to an extent according to its relative binding potency to the glucocorticoid receptor. In in vivo animal studies, loteprednol effectively inhibited allergically induced vascular leakage in the nasal cavity of actively sensitized Brown Norway rats and rhinorrhea in actively sensitized domestic pigs following nasal challenge. In several models of allergic asthma, loteprednol was able to suppress the allergically induced late-phase eosinophilia in mice, rats and guinea pigs. After intrapulmonary administration of loteprednol, only a slight, nonsignificant reduction in thymus weight was observed in a dose range far less than the therapeutically relevant doses. Its therapeutic ratio is clearly superior to those of beclomethasone and budesonide. Loteprednol is a safe steroid with an extremely wide range between therapeutic and side-effect-inducing doses. Its elimination profile, its pronounced binding to plasma protein and erythrocytes and its low oral bioavailability makes this drug highly suitable for nasal or pulmonary use.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.58	43.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

FILE 'MEDLINE' ENTERED AT 10:02:46 ON 24 AUG 2006

FILE 'EMBASE' ENTERED AT 10:02:46 ON 24 AUG 2006

FILE 'BIOSIS' ENTERED AT 10:02:46 ON 24 AUG 2006

=> s loteprednol or loteprednol etabonate
L6 374 LOTEPREDNOL OR LOTEPREDNOL ETABONATE

```
=> s asthma
L7      253257 ASTHMA

=> s L6 and L7
L8          35 L6 AND L7

=> dup rem L8
PROCESSING COMPLETED FOR L8
L9           24 DUP REM L8 (11 DUPLICATES REMOVED)

=> s L9 and (AY <2001 or PRY<2001 or PY <2001)
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
   1 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
L10          5 L9 AND (AY <2001 OR PRY<2001 OR PY <2001)

=> d 15 ibib abs
      5 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1-5

L10  ANSWER 1 OF 5     MEDLINE on STN
ACCESSION NUMBER:   2003330589     MEDLINE
DOCUMENT NUMBER:    PubMed ID: 12861354
TITLE:              Loteprednol etabonate: a soft steroid
                    for the treatment of allergic diseases of the airways.
AUTHOR:             Szelenyi I; Hochhaus G; Heer S; Kusters S; Marx D; Poppe H;
                    Engel J
CORPORATE SOURCE:   Pulmonary Pharmacology, Corporate Research & Development,
                    ASTA Medica, Frankfurt and Dresden, Germany.
SOURCE:             Drugs of today (Barcelona, Spain : 1998), (2000
                    May) Vol. 36, No. 5, pp. 313-20.
                    Journal code: 101160518. ISSN: 1699-3993.
PUB. COUNTRY:       Spain
DOCUMENT TYPE:      Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:           English
FILE SEGMENT:       NONMEDLINE; PUBMED-NOT-MEDLINE
ENTRY MONTH:        200310
ENTRY DATE:         Entered STN: 16 Jul 2003
                    Last Updated on STN: 25 Oct 2003
                    Entered Medline: 24 Oct 2003
AB   There are several approaches for developing new antiallergic/antiasthmatic
     agents.  One of them is the improvement of an existing class of effective
     drug classes.  Due to some undesired effects of intranasal or inhaled
     corticosteroids, there is a need for better tolerated corticosteroids.
     Loteprednol etabonate belongs to the so-called class of
     soft steroids because it is metabolized by a one-step reaction
     (hydrolysis) without using the cytochrome P450 monooxygenase system.  In
     in vitro investigations using human cells, loteprednol inhibited
     the release of proinflammatory cytokines (e.g., TNF-alpha, GM-CSF, IL-4,
     IL-5) according to its relative binding potency to the glucocorticoid
     receptor.  In in vivo animal studies, loteprednol effectively
     inhibited allergically induced vascular leakage in the nasal cavity of
     actively sensitized Brown Norway rats and rhinorrhea in actively
     sensitized domestic pigs following nasal challenge.  In several models of
     allergic asthma, it was clearly demonstrated that
     loteprednol was able to suppress the allergically induced late
     phase eosinophilia in mice, rats and guinea pigs.  After intrapulmonary
     administration of loteprednol, only a slight, statistically
     nonsignificant reduction in thymus weight was observed in a dose range far
```

less than the therapeutically relevant doses. Its therapeutic ratio is clearly superior to those of beclomethasone and budesonide. Loteprednol is a safe steroid with an extremely wide range between therapeutic and side effect inducing doses. Its elimination profile, its pronounced binding to plasma protein and erythrocytes and the low oral bioavailability makes this drug highly suitable for nasal or pulmonary use.

L10 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999314468 EMBASE
TITLE: Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.
AUTHOR: Crocker I.C.; Townley R.G.
CORPORATE SOURCE: Dr. R.G. Townley, Dept. of Medicine/Allergy Division, Creighton University, 2500 California Plaza, Omaha, NE 68178, United States
SOURCE: Drugs of Today, (1999) Vol. 35, No. 7, pp. 519-535. .
Refs: 137
ISSN: 0025-7656 CODEN: MDACAP
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 27 Sep 1999
Last Updated on STN: 27 Sep 1999

AB Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.

L10 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999273042 EMBASE
TITLE: The ideal steroid.
AUTHOR: Brattsand R.
CORPORATE SOURCE: R. Brattsand, Astra Draco AB, Preclinical R and D, PO Box 34, S-221 00 Lund, Sweden
SOURCE: Pulmonary Pharmacology and Therapeutics, (1999) Vol. 12, No. 2, pp. 119-122. .
Refs: 19
ISSN: 1094-5539 CODEN: PPTHFJ
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Pharmacology

037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Aug 1999
Last Updated on STN: 19 Aug 1999
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L10 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 1999218575 EMBASE
TITLE: Allergies: New treatment options and studies.
AUTHOR: Evans Y.
CORPORATE SOURCE: Y. Evans, Univ. of Mississippi Hosp./Clinics, Jackson, MS, United States
SOURCE: Drug Topics, (7 Jun 1999) Vol. 143, No. 11 SUPPL., pp. 10s-15s. .
ISSN: 0012-6616 CODEN: DGTNA7
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jul 1999
Last Updated on STN: 8 Jul 1999
AB For years, antihistamines, decongestants, and corticosteroids have been the mainstay in treating allergic disorders. Today, the pharmacotherapy options are expanding, and more clinical trials are being conducted to determine the best treatments for the various allergic disorders. When chronic diseases, such as allergic disorders, affect one in five North Americans, it is important that pharmacists stay abreast of the treatment options that are available and under investigation.

L10 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 1999056606 EMBASE
TITLE: New molecular entities approved in 1998.
SOURCE: Drug Topics, (1 Feb 1999) Vol. 143, No. 3, pp. 60-71. .
ISSN: 0012-6616 CODEN: DGTNA7
COUNTRY: United States
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Mar 1999
Last Updated on STN: 19 Mar 1999
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.17	62.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.25

FILE 'STNGUIDE' ENTERED AT 10:08:43 ON 24 AUG 2006